Starpharma Holdings Profit Margin 2011-2022 | SPHRY
Current and historical gross margin, operating margin and net profit margin for Starpharma Holdings (SPHRY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Starpharma Holdings net profit margin as of June 30, 2022 is 0%.
| Starpharma Holdings Annual Profit Margins |
| Starpharma Holdings Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.160B |
$0.004B |
|
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
|
